Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870425 | 0.93 | SYK (0.38) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL4869547 | 0.92 | SYK (0.37) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL4867740 | 0.92 | SYK (0.38) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL4862738 | 0.92 | SYK (0.37) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL4870741 | 0.92 | SYK (0.37) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL6232490 | 0.91 | SYK (0.37) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL4866348 | 0.86 | SYK (0.36) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL4864629 | 0.83 | GAA (0.41) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL1596261 | 0.77 | GAA (0.38) | SYKGAATAS2R14PRMT5WDR77 | |
| SCHEMBL1596263 | 0.77 | GAA (0.38) | SYKGAATAS2R14PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | SYK 4390/4885GAA 1043/4885TAS2R14 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.